Approval and Availability
Eli Lilly and Company (India) has introduced Mounjaro® in a single-dose vial format after receiving marketing authorization from the Central Drugs Standard Control Organization (CDSCO). This innovative treatment is the first of its kind, activating both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.
Indications and Usage
As per the press release, Mounjaro® supports chronic weight management when combined with a reduced-calorie diet and increased physical activity. It is recommended for:
- Obese adults (BMI ≥30 kg/m²)
- Overweight adults (BMI ≥27 kg/m²) with at least one weight-related comorbidity
Additionally, Mounjaro® helps improve glycemic control in adults with type 2 diabetes mellitus when used alongside diet and exercise.
Addressing India’s Health Challenge
Obesity and type 2 diabetes are growing public health concerns in India. Winselow Tucker, President and General Manager of Lilly India, emphasized the company’s commitment to collaborating with the government and industry to enhance awareness, prevention, and management of these diseases.
Commitment to Innovation
Eli Lilly India is accelerating the introduction of cutting-edge treatments to improve patient outcomes. The launch of Mounjaro® reinforces the company’s mission to enhance the lives of people with obesity and diabetes, aligning with its vision for a healthier India.